PaxMedica (PXMD) Competitors $0.0002 0.00 (0.00%) As of 09/4/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsInsider TradesSEC FilingsShort InterestTrendsBuy This Stock PXMD vs. CMRA, GNCAQ, GNCA, ARDS, AMPE, HSTO, CALA, CLVR, EFTR, and ONCSQShould you be buying PaxMedica stock or one of its competitors? The main competitors of PaxMedica include Comera Life Sciences (CMRA), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), Aridis Pharmaceuticals (ARDS), Ampio Pharmaceuticals (AMPE), Histogen (HSTO), Calithera Biosciences (CALA), Clever Leaves (CLVR), eFFECTOR Therapeutics (EFTR), and OncoSec Medical (ONCSQ). These companies are all part of the "pharmaceutical products" industry. PaxMedica vs. Its Competitors Comera Life Sciences Genocea Biosciences Genocea Biosciences Aridis Pharmaceuticals Ampio Pharmaceuticals Histogen Calithera Biosciences Clever Leaves eFFECTOR Therapeutics OncoSec Medical Comera Life Sciences (NASDAQ:CMRA) and PaxMedica (NASDAQ:PXMD) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations, institutional ownership and media sentiment. Which has better valuation & earnings, CMRA or PXMD? Comera Life Sciences has higher revenue and earnings than PaxMedica. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioComera Life Sciences$1.00M0.01-$18MN/AN/APaxMedicaN/AN/A-$18.29MN/AN/A Does the media favor CMRA or PXMD? In the previous week, Comera Life Sciences' average media sentiment score of 0.00 equaled PaxMedica'saverage media sentiment score. Company Overall Sentiment Comera Life Sciences Neutral PaxMedica Neutral Do insiders and institutionals believe in CMRA or PXMD? 4.9% of PaxMedica shares are held by institutional investors. 8.9% of Comera Life Sciences shares are held by company insiders. Comparatively, 1.0% of PaxMedica shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Is CMRA or PXMD more profitable? Comera Life Sciences' return on equity of 0.00% beat PaxMedica's return on equity.Company Net Margins Return on Equity Return on Assets Comera Life SciencesN/A N/A N/A PaxMedica N/A -3,167.89%-560.35% Which has more risk & volatility, CMRA or PXMD? Comera Life Sciences has a beta of 1.28, indicating that its stock price is 28% more volatile than the S&P 500. Comparatively, PaxMedica has a beta of -0.99, indicating that its stock price is 199% less volatile than the S&P 500. SummaryComera Life Sciences beats PaxMedica on 6 of the 7 factors compared between the two stocks. Get PaxMedica News Delivered to You Automatically Sign up to receive the latest news and ratings for PXMD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PXMD vs. The Competition Export to ExcelMetricPaxMedicaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2K$865.53M$5.77B$9.91BDividend YieldN/A4.84%6.67%4.51%P/E RatioN/A1.1475.7426.65Price / SalesN/A26.53557.21121.56Price / CashN/A19.5637.1158.92Price / Book0.006.7711.446.07Net Income-$18.29M-$4.20M$3.28B$266.32M7 Day PerformanceN/A0.23%0.63%0.06%1 Month PerformanceN/A10.24%6.89%3.90%1 Year PerformanceN/A26.47%59.40%23.68% PaxMedica Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PXMDPaxMedicaN/A$0.00flatN/AN/A$2KN/A0.002CMRAComera Life SciencesN/A$0.00flatN/AN/A$6K$1.00M0.002GNCAQGenocea BiosciencesN/AN/AN/AN/A$6KN/A0.0070GNCAGenocea BiosciencesN/AN/AN/AN/A$6K$1.91M0.0070ARDSAridis PharmaceuticalsN/A$0.00-99.8%N/AN/A$5KN/A0.0030Gap DownAMPEAmpio PharmaceuticalsN/A$0.00-96.8%N/A+22.7%$3KN/A0.0020HSTOHistogenN/A$0.00+66.7%N/A-99.8%$2K$19K0.0020CALACalithera BiosciencesN/A$0.00flatN/A-99.0%$1KN/A0.0060Gap DownCLVRClever LeavesN/A$0.00flatN/AN/A$1K$17.42M0.00560EFTReFFECTOR TherapeuticsN/A$0.00flatN/A-99.4%$1KN/A0.0010ONCSQOncoSec MedicalN/AN/AN/AN/A$1KN/A0.0040 Related Companies and Tools Related Companies CMRA Alternatives GNCAQ Alternatives GNCA Alternatives ARDS Alternatives AMPE Alternatives HSTO Alternatives CALA Alternatives CLVR Alternatives EFTR Alternatives ONCSQ Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PXMD) was last updated on 9/5/2025 by MarketBeat.com Staff From Our PartnersHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PaxMedica, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PaxMedica With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
